Chemotherapeutic Options

[Merridith]

This is a 6 page article:


Introduction
Can Schedule/Sequence Alterations Affect Outcomes?
Evaluating New Therapeutic Regimens in the Metastatic Setting
Future Directions in Chemotherapeutic Management
Conclusions
References

http://www.medscape.com/viewarticle/491728

[al from canada]

Great article Merridith.
One thing all of these articles refers to is Response Rate, Time to Disease Progression (TTP), and Overall Survival (OS). My question is: many of these novel therapies or novel combinations have a significantly different TTP but have a non-significant OS. In otherwords, why is it if we can stall the TTP you still died just as early as the lower TTP study arm? Is this a statistical anomoly or a medical fact?
Al